Business
The BARD1 (ASX:BD1) share price eyes record highs after positive research results
The BARD1 Life Sciences (ASX: BD1) share price is on watch today after positive results from the evaluation of its EXO-NET product in pancreatic cancer.
Let’s take a closer look at the announcement and what this means for the BARD1 share price.
What’s driving the BARD1 share price higher?
BARD1 maintains a cancer diagnostics portfolio. This includes the commercialised hTRET test which is used as a supplement to urine cytology tests. Additionally, the portfolio also includes diagnostics tests in development for ovarian, breast, lung, prostate, and pancreatic cancers. The group is working towards commercialising its…
-
Business14 hours agoWarning! These ASX 200 shares were just downgraded
-
Business12 hours ago2 monthly payers you’ll want to own in 2025 and beyond
-
General23 hours agoTelco Exetel fined $694K after scammers bypass verification processes, access bank accounts
-
General22 hours agoSergio Perez and Valtteri Bottas to return to Formula 1 with Cadillac